Bora Pharmaceuticals CoTPE:6472 +1.74%87 Gross Margin % is 36.46% as of Dec. 2025, which is 9% below its 10-year median of 40.21. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$717.57 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 935 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks worse than 62.67% on this metric.
TPE:6472's Gross Margin % is ranked worse than 62.67% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs TPE:6472: 41.30
Bora Pharmaceuticals Co had a gross margin of 36.46% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Bora Pharmaceuticals Co was 4.80% per year.
Bora Pharmaceuticals Co (TPE:6472) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bora Pharmaceuticals Co had a gross margin of 36.46% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bora Pharmaceuticals Co Gross Margin % Related Terms
Bora Pharmaceuticals Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bora Pharmaceuticals Co (TPE:6472) has a Gross Margin % of 36.46% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Bora Pharmaceuticals Co and its competitors. This is near median its historical median of 40.21. Over the past decade, Bora Pharmaceuticals Co's Gross Margin % has ranged from 27.76 to 49.23. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #586 out of 935 companies in the Drug Manufacturers industry, placing it in the top 62.7%.
Is Bora Pharmaceuticals Co's Gross Margin % too high?
Bora Pharmaceuticals Co's current Gross Margin % of 36.46% is near median its 10-year median of 40.21. Over the past 10 years, this metric has ranged from a low of 27.76 to a high of 49.23. The Drug Manufacturers industry median Gross Margin % is 48.46. Bora Pharmaceuticals Co's value of 36.46% is 24.8% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #586 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #586 out of 935 companies for Gross Margin %. This places Bora Pharmaceuticals Co in the lower half of its industry. The industry median Gross Margin % is 48.46. Bora Pharmaceuticals Co's value of 36.46% is 24.8% below this benchmark. Historically, Bora Pharmaceuticals Co's own Gross Margin % has ranged from 27.76 to 49.23 over the past decade. While the company's 10-year median is 40.21 vs. the industry median of 48.46, Bora Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current Gross Margin % of 36.46% is 24.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current Gross Margin % is 36.46%, which is near median its own 10-year median of 40.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$717.57, compared to a current price of NT$439.50 — trading 38.8% below its estimated fair value. The current Gross Margin % is 36.46%, which is near median its 10-year median of 40.21 and 24.8% below the Drug Manufacturers industry median of 48.46. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Gross Margin % is 36.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$439.50 is trading 38.8% below its estimated GF Value™ of NT$717.57.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
Gross Margin %: 36.46% (near median its 10-year median of 40.21)
GF Value™: NT$717.57 vs. price of NT$439.50 (38.8% below fair value)
Industry Position: 24.8% below the Drug Manufacturers median (#586 of 935)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
